BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TransThera Sciences (Nanjing)\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies TransThera Sciences (Nanjing)\, I
 nc.'s drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05948475-9067@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tinengotinib: Phase 3 readout est. (NCT05948475)
DESCRIPTION:Tinengotinib\, phase 3\, Cholangiocarcinoma.\nStudy: Study of T
 inengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-alter
 ed in Cholangiocarcinoma\nEstimated primary completion: December 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/tinengotinib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05948475
URL:https://assetmemo.bio/drug/tinengotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07498478-9067@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tinengotinib: Phase 2 readout est. (NCT07498478)
DESCRIPTION:Tinengotinib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestran
 t Injection in Patients With HR Positive and HER-2 Negative Recurrent or M
 etastatic Breast Cancer Who Have Failed Prior Treatment\nEstimated primary
  completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/tinengotinib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07498478
URL:https://assetmemo.bio/drug/tinengotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07871110-9067@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Tinengotinib: Phase 2 readout est. (NCT07871110)
DESCRIPTION:Tinengotinib\, phase 2.\nStudy: Safety\, Efficacy and Pharmacok
 inetics of TT00420 Tablets Combined With Novel Endocrine Therapy in Patien
 ts With Metastatic Castration-resistant Prostate Cancer (mCRPC)\nEstimated
  primary completion: 31 December 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/tinengotinib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07871110
URL:https://assetmemo.bio/drug/tinengotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07328919-9067@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Tinengotinib: Phase 3 readout est. (NCT07328919)
DESCRIPTION:Tinengotinib\, phase 3\, Cholangiocarcinoma.\nStudy: Efficacy a
 nd Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patien
 ts With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/R
 earrangements or Mutations\nEstimated primary completion: 31 December 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/tinengotinib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07328919
URL:https://assetmemo.bio/drug/tinengotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
